SCHEMBL20189877

SCHEMBL20189877

CC(C)(N)c1ccc(CN2CC(=O)NC2=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.44
EPHX2 P34913 1/20 0.43
DDB1 Q16531 2/20 0.43
CRBN Q96SW2 2/20 0.43
HDAC6 Q9UBN7 2/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
POLB P06746 2/20 0.39
MAPK1 P28482 1/20 0.37
PPARG P37231 2/20 0.36
PPARD Q03181 2/20 0.36
PPARA Q07869 2/20 0.36
ALDH1A1 P00352 6/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ENPP2 Q13822 1/20 0.35
MAPT P10636 1/20 0.35
DPP4 P27487 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20189726 0.86 GAA (0.43) GAAEPHX2DDB1CRBNHDAC6
SCHEMBL8009140 0.80 EPHX2 (0.47) GAAEPHX2DDB1CRBNHDAC6
SCHEMBL20189142 0.80 EPHX2 (0.47) GAAEPHX2DDB1CRBNHDAC6
SCHEMBL20189796 0.79 GAA (0.39) GAAEPHX2DDB1CRBNHDAC6
SCHEMBL9164640 0.78 EPHX2 (0.49) GAAEPHX2DDB1CRBNHDAC6
SCHEMBL28757730 0.77 EPHX2 (0.47) GAAEPHX2DDB1CRBNHDAC6
SCHEMBL840894 0.77 EPHX2 (0.47) GAAEPHX2DDB1CRBNHDAC6
SCHEMBL9850086 0.76 DDB1 (0.69) GAAEPHX2DDB1CRBNHDAC6
SCHEMBL1011633 0.76 DDB1 (0.69) GAAEPHX2DDB1CRBNHDAC6
SCHEMBL6101068 0.76 GAA (0.73) GAAHDAC6ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168059-B2 Amino sulfonyl compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-09 US disclosed
US-11168059-B2 Amino sulfonyl compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-09 US disclosed
US-20190330158-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-10-31 US disclosed
US-20190330158-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-10-31 US disclosed
WO-2018098209-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168059-B2 Amino sulfonyl compounds DPYD, DNPEP, DUT GAA 148/4885EPHX2 2947/4885DDB1 33/4885
US-20190330158-A1 AMINO SULFONYL COMPOUNDS DPYD, DNPEP, DUT GAA 148/4885EPHX2 2947/4885DDB1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.